This is a database of novel vaccine candidates designed to provide broader and more durable protection against circulating and pandemic influenza viruses. The database includes investigational technologies that have reached clinical or late preclinical stages of development.
A single dose of the typhoid conjugate vaccine was immunogenic and effective in reducing Salmonella Typhi bacteremia in children nine months to 16 years of age.
Despite significant gains in understanding of Shigella infection, it remains unknown how the bacteria initiate contact with the colonic epithelium. This research identified conditions that mimic some features of gastrointestinal transit and that enable Shigella to express adherence structural genes.
Investigational therapeutics mAb114 and REGN-EB3 offer patients a greater chance of surviving Ebola virus disease compared to the investigational treatment ZMapp, according to published results from a clinical trial conducted in the Democratic Republic of the Congo (DRC).
Researchers demonstrated a new strategy for engineering a live bacterial vaccine that has been rationally-designed to optimize both protection and diagnostic compatibility.
A survey was conducted by the Nakuru Regional Veterinary Investigation Laboratory (RVIL) found that foot and mouth disease (FMD) is prevalent on farms where owners keep cattle as a ‘side hustle’, are headed by females and are aged 36-60 as many increasingly give their animals local brew.
Pakistan began vaccinating millions of children against typhoid on Friday, November 15, in response to a drug-resistant superbug outbreak of the fever that has already infected 11,000 people since 2016 and risks spreading internationally.
Japan's Health Ministry said that antidote auto-injections by non-medical professionals will be permitted should toxic agents be dispersed in a terrorist attack. This is in preparation for next year’s Tokyo Olympics.
Researchers assigned 440 participants to receive two doses of MVA followed by one dose of the established replicating-vaccinia vaccine ACAM2000 (the MVA group) or to receive one dose of ACAM2000 (the ACAM2000-only group). No safety concerns associated with the MVA vaccine were identified, and immune responses and attenuation of the major cutaneous reaction suggest the MVA vaccine protected against variola infection.
Tychan‘s monoclonal antibody candidate treatment for Yellow Fever has successfully completed Phase 1A/1B safety trials in Singapore.